论文部分内容阅读
耐药菌的出现对全球公共卫生构成了巨大的挑战,结核分枝杆菌(TB)是结核病的病原菌,是临床上最重要的病原体之一。新抗生素的研发用以治疗耐药性结核病已成为临床及公共卫生管理亟待解决的重要问题。生物素(维生素B7)在结核杆菌的代谢途径如脂肪酸合成和三羧酸循环中发挥重要作用,通过生物素蛋白连接酶连接活性辅助因子而被激活。生物素蛋白连接酶及其相关生物合成通路是微生物合成生物素过程中必不可或缺的关键分子,因而有可能成为新的药物靶点。遗传研究表明,结核杆菌需要由菌体进行生物素的全程合成,因此,生物素合成酶在在结核杆菌代谢过程中起着至关重要的作用,引起了抗结核药物研究者的高度重视。本文论述了结核杆菌生物素合成通路,并重点分析了生物素合成过程中可能成为药物靶点的关键酶,旨在为结核病的治疗提供新思路,具有重要的临床意义。
The emergence of drug-resistant bacteria pose a huge challenge to global public health. Mycobacterium tuberculosis (TB) is the pathogen of tuberculosis and one of the most clinically important pathogens. The development of new antibiotics to treat drug-resistant tuberculosis has become an important issue to be solved in clinical and public health management. Biotin (vitamin B7) plays an important role in M. tuberculosis metabolic pathways such as fatty acid synthesis and tricarboxylic acid cycling, and is activated by the attachment of active cofactors to the biotin ligase. Biotin ligases and their related biosynthetic pathways are essential molecules in biosynthesis of biotin and are therefore likely to become new drug targets. Genetic studies have shown that Mycobacterium tuberculosis requires biotin synthesis from the cell body, therefore, biotin synthase plays a crucial role in the metabolism of Mycobacterium tuberculosis, causing researchers of anti-TB drugs to attach great importance. This article discusses the biotin synthesis pathway of Mycobacterium tuberculosis and focuses on the key enzyme that may become the drug target in biotin synthesis. It aims to provide new ideas for the treatment of tuberculosis and has important clinical significance.